Abstract
Acetylcholinesterase has long been considered as a target for Alzheimer disease therapy. In this work, several classification models were built for the purpose of distinguishing acetylcholinesterase inhibitors (AChEIs) and decoys. Each molecule was initially represented by 211 ADRIANA.Code and 334 MOE descriptors. Correlation analysis, F-score and attribute selection methods in Weka were used to find the best reduced set of descriptors, respectively. Additionally, models were built using a Support Vector Machine and evaluated by 5-, 10-fold and leave-one-out cross-validation. The best model gave a Matthews Correlation Coefficient (MCC) of 0.99 and a prediction accuracy (Q) of 99.66% for the test set. The best model also gave good result on an external test set of 86 compounds (Q=96.51%, MCC=0.93). The descriptors selected by our models suggest that H-bond and hydrophobicity interactions are important for the classification of AChEIs and decoys.
Keywords: Acetylcholinesterase inhibitor (AChEI), correlation analysis, F-score, support vector machines (SVM), weka, Alzhemier disease, H-bond, hydrophobiciyty, drug discovery process
Combinatorial Chemistry & High Throughput Screening
Title:Classification of Acetylcholinesterase Inhibitors and Decoys by a Support Vector Machine
Volume: 15 Issue: 6
Author(s): Kai Wang, Xiaoying Hu, Zhi Wang and Aixia Yan
Affiliation:
Keywords: Acetylcholinesterase inhibitor (AChEI), correlation analysis, F-score, support vector machines (SVM), weka, Alzhemier disease, H-bond, hydrophobiciyty, drug discovery process
Abstract: Acetylcholinesterase has long been considered as a target for Alzheimer disease therapy. In this work, several classification models were built for the purpose of distinguishing acetylcholinesterase inhibitors (AChEIs) and decoys. Each molecule was initially represented by 211 ADRIANA.Code and 334 MOE descriptors. Correlation analysis, F-score and attribute selection methods in Weka were used to find the best reduced set of descriptors, respectively. Additionally, models were built using a Support Vector Machine and evaluated by 5-, 10-fold and leave-one-out cross-validation. The best model gave a Matthews Correlation Coefficient (MCC) of 0.99 and a prediction accuracy (Q) of 99.66% for the test set. The best model also gave good result on an external test set of 86 compounds (Q=96.51%, MCC=0.93). The descriptors selected by our models suggest that H-bond and hydrophobicity interactions are important for the classification of AChEIs and decoys.
Export Options
About this article
Cite this article as:
Wang Kai, Hu Xiaoying, Wang Zhi and Yan Aixia, Classification of Acetylcholinesterase Inhibitors and Decoys by a Support Vector Machine, Combinatorial Chemistry & High Throughput Screening 2012; 15 (6) . https://dx.doi.org/10.2174/138620712800563891
DOI https://dx.doi.org/10.2174/138620712800563891 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science AD Vaccines: Conclusions and Future Directions
CNS & Neurological Disorders - Drug Targets The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Subtype Classification by Polymerase and Gag Genes of HIV-1 Iranian Sequences Registered in the NCBI GenBank
Current Proteomics Attentional Set-Shifting in Rodents: A Review of Behavioural Methods and Pharmacological Results
Current Pharmaceutical Design Advances in Adjuvant Therapy Against Acute Bacterial Meningitis
Current Drug Targets - Infectious Disorders Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets Natural Phytochemicals and Their Therapeutic Role in Management of Several Diseases: A Review
Current Traditional Medicine Nanotechnology Approaches to Target Endosomal pH: A Promising Strategy for an Efficient Intracellular Drug, Gene and Protein Delivery
Drug Delivery Letters Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer’s Disease
Current Medicinal Chemistry Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Treatment of Insulin Resistance in the Neurodegeneration
Recent Patents on CNS Drug Discovery (Discontinued) Chemical and Pharmacological Aspects of Heteroaryl-Nitrones
Current Medicinal Chemistry